Skip to main content
. Author manuscript; available in PMC: 2015 Apr 15.
Published in final edited form as: Free Radic Biol Med. 2010 Jul 13;49(6):1119–1128. doi: 10.1016/j.freeradbiomed.2010.06.030

Fig. 3.

Fig. 3

Various portions of the ICAM-1 cytoplasmic tail modulate both GSH levels and GCL activity. (A) The complete amino acid sequence for the AP-ICAM as well as TD1, TD2, and TD3 peptides in conjunction with the purported function of each segment. (B) GSH levels after cellular treatment with AP-ICAM and the three variations of the cytoplasmic tail peptide. (C) GCL activity after cellular treatment with AP-ICAM and the three variations of the cytoplasmic tail peptide. n=5; #p<0.001, *p<0.01; experiments performed in quadruplicate.